Shenzhen Hepalink Pharmaceutical Group Co (HKSE:09989) Long-Term Debt: HK$32 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:09989 Shenzhen Hepalink Pharmaceutical Group Co Ltd HKSE:09989
84 GF Score
Price HK$4.16
GF Value HK$4.71
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Shenzhen Hepalink Pharmaceutical Group Co Long-Term Debt?

Shenzhen Hepalink Pharmaceutical Group Co HKSE:09989 -0.95% 84 Long-Term Debt is HK$32 Mil as of Jun. 2026. GuruFocus rates HKSE:09989 with a GF Score™ of 84/100 and a GF Value™ of HK$4.71 (Modestly Undervalued). The stock has 6 warning signs investors should review.

Shenzhen Hepalink Pharmaceutical Group Co's Long-Term Debt for the quarter that ended in Jun. 2026 was HK$32 Mil.

Shenzhen Hepalink Pharmaceutical Group Co's quarterly Long-Term Debt declined from Dec. 2025 (HK$329 Mil) to Mar. 2026 (HK$33 Mil) and declined from Mar. 2026 (HK$33 Mil) to Jun. 2026 (HK$32 Mil).

Shenzhen Hepalink Pharmaceutical Group Co's annual Long-Term Debt declined from Dec. 2023 (HK$1,980 Mil) to Dec. 2024 (HK$1,154 Mil) and declined from Dec. 2024 (HK$1,154 Mil) to Dec. 2025 (HK$329 Mil).

Shenzhen Hepalink Pharmaceutical Group Co  (HKSE:09989) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Shenzhen Hepalink Pharmaceutical Group Co Long-Term Debt Related Terms

Shenzhen Hepalink Pharmaceutical Group Co Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Shenzhen Hepalink Pharmaceutical Group Co's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shenzhen Hepalink Pharmaceutical Group Co Long-Term Debt Chart

Shenzhen Hepalink Pharmaceutical Group Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,755.38 2,564.74 1,979.76 1,154.21 329.27

Shenzhen Hepalink Pharmaceutical Group Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 577.32 476.25 329.27 32.61 31.76
HKSE:09989
84GF Score
Shenzhen Hepalink Pharmaceutical Group Co Ltd HKSE:09989
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of HK$32 Mil mean?
Shenzhen Hepalink Pharmaceutical Group Co (HKSE:09989) has a Long-Term Debt of HK$32 Mil as of Jun. 2026.
Is Shenzhen Hepalink Pharmaceutical Group Co's Long-Term Debt too high?
Shenzhen Hepalink Pharmaceutical Group Co's current Long-Term Debt is HK$32 Mil. Overall, Shenzhen Hepalink Pharmaceutical Group Co has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shenzhen Hepalink Pharmaceutical Group Co's Long-Term Debt compare to ZTS?
Shenzhen Hepalink Pharmaceutical Group Co's Long-Term Debt of HK$32 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Drug Manufacturers company?
A good Long-Term Debt depends on the Drug Manufacturers industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Shenzhen Hepalink Pharmaceutical Group Co's current Long-Term Debt is HK$32 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shenzhen Hepalink Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Shenzhen Hepalink Pharmaceutical Group Co (HKSE:09989) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$4.71, compared to a current price of HK$4.16 — trading 11.8% below its estimated fair value. The current Long-Term Debt is HK$32 Mil. Shenzhen Hepalink Pharmaceutical Group Co's overall GF Score™ is 84/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Shenzhen Hepalink Pharmaceutical Group Co (HKSE:09989), the current Long-Term Debt is HK$32 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shenzhen Hepalink Pharmaceutical Group Co (HKSE:09989) Overvalued in 2026?

Based on GuruFocus' analysis, Shenzhen Hepalink Pharmaceutical Group Co stock appears to be undervalued. The current stock price of HK$4.16 is trading 11.8% below its estimated GF Value™ of HK$4.71. GuruFocus considers Shenzhen Hepalink Pharmaceutical Group Co to be Modestly Undervalued.

Key valuation signals for HKSE:09989:

  • Long-Term Debt: HK$32 Mil
  • GF Value™: HK$4.71 vs. price of HK$4.16 (11.8% below fair value)
  • GF Score™: 84/100 with 6 warning signs

No single metric tells the full story. See the HKSE:09989 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shenzhen Hepalink Pharmaceutical Group Co Business Description

Other Exchanges 002399:China
Address No. 21 Langshan Road, Songping Mountain, Guangdong Province, Nanshan District, Shenzhen, CHN, 518057
Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based company. Along with its subsidiary, it is engaged in biopharmaceutical production, biopharmaceutical services, biopharmaceutical trading, and biopharmaceutical research and development in Asia, Europe, North America, and Australia, and investment business in Asia and North America. The Group mainly operates three main business segments, including the Finished dose pharmaceutical products; Active pharmaceutical ingredients; CDMO business; and Others. The geographical presence of the company is in Hong Kong, the United States of America, Europe, Mainland China, and Other countries. The majority of the company's revenue comes from Europe and the USA.
84GF Score

Get the complete analysis for HKSE:09989

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$4.16
Price
HK$4.71
GF Value